Abu Dhabi-based artificial intelligence and cloud computing company Group 42 defines the current state of AI development as “artificial narrow intelligence” — that is, technology focused on solving problems for a specific set of situations and industries. The company’s near-term projects tackle autonomous driving, along with medical robotics, fraud detection and high-frequency trading, as well as cognitive tasks such as voice analytics, image recognition, text mining and video understanding, for government, healthcare, finance, aviation and smart cities.
G42 has also leveraged its technology to play a significant role in fighting Covid-19 – establishing a massive throughput laboratory to speed up the detection of the disease; manufacturing essential PPE; conducting research into new vaccines and drug therapies; and using its advanced AI capabilities to map and predict trends and virus mutations in the outbreak.
It also partnered with Chinese pharmaceutical group Sinopharm CNBG to conduct the world’s first Phase III trials of the inactivated Covid-19 vaccine in Abu Dhabi, under the administration of the UAE Ministry of Health (MOH) and the Department of Health Abu Dhabi (DOH).
However, its brief doesn’t stop there. The firm is also working towards the future definition of AI, where have the capacity to handle general tasks in a similar way to humans, which it has dubbed “the age of artificial general intelligence”.